# Legend Biotech Corp > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Legend Biotech Corp). ## Overview Legend Biotech Corp is a cell therapy company focused on discovering, developing, manufacturing, and commercializing novel treatments for cancer and other serious diseases. Its core business is built around CARVYKTI®, a CAR-T therapy developed and marketed with Johnson & Johnson, alongside a pipeline of next-generation cell therapy programs. ## Products & services • CARVYKTI® CAR-T therapy for relapsed/refractory multiple myeloma • Cell therapy research and early-stage pipeline development • Clinical development and regulatory advancement of oncology therapies • Manufacturing and commercialization of autologous cell therapies • Collaboration-based development with Johnson & Johnson - **Commercial cell therapy** (95%) — Approved CAR-T treatments sold through a collaboration model, centered on CARVYKTI®. - **License and other revenue** (5%) — Milestone, royalty, and other non-product revenue tied to collaboration arrangements. - **Clinical pipeline programs** (0%) — Investigational cell therapy candidates advancing through preclinical and clinical development. - CARVYKTI® CAR-T therapy for relapsed/refractory multiple myeloma - Cell therapy research and early-stage pipeline development - Clinical development and regulatory advancement of oncology therapies - Manufacturing and commercialization of autologous cell therapies - Collaboration-based development with Johnson & Johnson ## Customers Legend Biotech serves patients through the healthcare system, with treatment adoption driven by hematologists, oncologists, and transplant centers that administer CAR-T therapies. A major commercial counterpart is Johnson & Johnson, with whom the company collaborates on CARVYKTI® development and marketing. Its end market is the oncology treatment segment, especially patients with relapsed or refractory multiple myeloma and other difficult-to-treat cancers. - **Oncology treatment centers** (primary) — Hospitals and specialty centers that purchase and administer CARVYKTI® to eligible patients. - **Multiple myeloma patients** (primary) — Patients with relapsed or refractory disease who receive CARVYKTI® as a one-time CAR-T treatment. - **Johnson & Johnson collaborator** (primary) — Strategic partner involved in development and commercialization of CARVYKTI®. - **Clinical research network** (secondary) — Investigators and trial sites that support testing of next-generation cell therapy assets. - Oncology specialists prescribing CAR-T therapy for eligible cancer patients - Hospitals and infusion centers that administer and monitor treatment - Patients with relapsed or refractory multiple myeloma - Johnson & Johnson as development and commercialization collaborator - Clinical trial sites supporting pipeline advancement ## Geography Legend Biotech is centered in the United States, where it develops and commercializes its core therapy and anchors most of its operating footprint. Its commercialization reach extends into Europe and Japan through CARVYKTI® approvals, while development activity also includes regulatory pathways in China. Because its business is tied to global oncology approvals and clinical sites, geography affects market access, launch timing, and regulatory execution. - **United States** (60%) — Core operating base and primary commercial market - **Europe** (20%) — Commercial approval in Europe - **Asia-Pacific** (20%) — Japan commercialization and China development exposure - United States is the core operating and commercial center - Europe is an important approved market for CARVYKTI® - Japan is a commercial market with product approval - China is relevant for development and regulatory progress - Global clinical and manufacturing footprint supports cell therapy delivery ## Strategy Legend Biotech is building an end-to-end cell therapy company around CARVYKTI® while expanding the product’s patient access and therapeutic reach. Its strategy also includes advancing next-generation cell therapy modalities beyond multiple myeloma, including work aimed at harder-to-treat solid tumors. Collaboration with Johnson & Johnson remains central because it broadens commercialization capacity and supports market penetration. - **Maximize CARVYKTI® patient access** (short-term) — CARVYKTI® is the company’s core commercial asset and the main driver of adoption. - **Advance next-generation cell therapy pipeline** (medium-term) — Pipeline breadth reduces dependence on one product and supports long-term growth. - **Deepen collaboration execution** (medium-term) — The Johnson & Johnson partnership improves commercialization reach and development scale. - Expand CARVYKTI® access across key oncology markets - Strengthen end-to-end capabilities in cell therapy - Advance next-generation pipeline candidates - Broaden the platform beyond hematologic cancers - Leverage the Johnson & Johnson collaboration ## Risks Legend Biotech depends heavily on the clinical, regulatory, and commercial success of CARVYKTI®, so any disruption to uptake, manufacturing, or safety perception can affect the business materially. Cell therapy development is also scientifically and operationally complex, with long development cycles, uncertain trial outcomes, and significant dependence on specialized manufacturing and treatment infrastructure. Global approvals and reimbursement dynamics add region-specific execution risk, especially where access and launch timing vary by market. - **Product concentration in CARVYKTI®** [high] — A large share of the business is tied to one commercial therapy. - **Clinical development uncertainty** [high] — Pipeline candidates may fail in preclinical or clinical testing. - **Manufacturing and supply chain execution** [high] — CAR-T therapies require specialized manufacturing, logistics, and chain-of-custody controls. - **Regulatory and market access delays** [medium] — Approvals, label expansion, and reimbursement differ across regions. - **Collaboration dependence** [medium] — Commercialization and development are partly shared with Johnson & Johnson. - Concentration risk in CARVYKTI® - Clinical trial and pipeline failure risk - Manufacturing complexity and capacity constraints - Regulatory and reimbursement timing risk - Dependence on Johnson & Johnson collaboration ## Accounting Legend Biotech’s reported revenue includes collaboration revenue and smaller license and other revenue, so the timing of partner milestones and related performance obligations can affect quarter-to-quarter results. The business also relies on judgment around clinical development costs, intangible assets, and potential impairment or fair value assessments, which are important in a research-intensive cell therapy model. Because operations span multiple countries and a collaboration structure, foreign exchange translation and allocation of shared costs can also affect reported profitability trends. - **Collaboration revenue recognition** — Can shift revenue between quarters and affect comparability - **License and milestone accounting** — Can create lumpy revenue patterns - **R&D expense measurement** — Affects operating loss and investment intensity - **Foreign exchange translation** — Can affect reported comprehensive income - Collaboration revenue timing affects quarter-to-quarter comparability - License and other revenue may depend on milestone recognition - R&D expense capitalization and expensing judgments matter - Foreign currency translation affects consolidated results - Impairment and valuation judgments matter for biotech assets --- *Last updated: 2026-09-28T12:04:17.839070+00:00*